Purple Biotech Reports Preclinical Proof of Concept
Ticker: PPBT · Form: 6-K · Filed: Mar 14, 2024 · CIK: 1614744
Sentiment: neutral
Topics: biotech, preclinical, technology
TL;DR
Purple Biotech's Tribody tech shows preclinical promise, filing details March 14th.
AI Summary
On March 14, 2024, Purple Biotech Ltd. announced positive preclinical results for its Tribody platform technology. The study demonstrated proof of concept, showing the platform's potential in a specific application. This announcement was made via a press release filed with the SEC.
Why It Matters
Positive preclinical data is a crucial step in drug development, indicating potential for future clinical trials and market viability.
Risk Assessment
Risk Level: medium — Preclinical results are early-stage and do not guarantee success in human trials or commercialization.
Key Players & Entities
- Purple Biotech Ltd. (company) — The company filing the report and announcing the results.
- March 14, 2024 (date) — The date the press release was issued and the filing was made.
- Tribody Platform Technology (technology) — The platform technology for which preclinical results were reported.
FAQ
What specific application was the Tribody platform technology tested in for the preclinical proof of concept?
The filing does not specify the exact application, only that a 'preclinical proof of concept' was achieved for the Tribody platform technology.
When was the press release announcing these results issued?
The press release was issued on March 14, 2024.
What is the company's primary business area?
Purple Biotech Ltd. is in the Pharmaceutical Preparations industry (SIC code 2834).
What is the company's SEC file number?
The SEC file number for Purple Biotech Ltd. is 001-37643.
Has Purple Biotech Ltd. changed its name previously?
Yes, the company was formerly known as Kitov Pharma Ltd. (name change effective January 25, 2018) and Kitov Pharmaceuticals Holdings Ltd. (name change effective July 24, 2014).
Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-03-14 07:40:25
Filing Documents
- ea0201801-6k_purplebio.htm (6-K) — 19KB
- ea020180101ex99-1_purplebio.htm (EX-99.1) — 14KB
- 0001213900-24-022370.txt ( ) — 34KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. March 14, 2024 PURPLE BIOTECH LTD. By: /s/ Lior Fhima Lior Fhima Chief Financial Officer 2